Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder

Paper. Morland LA, Khalifian CE, Perivoliotis D et al.. Journal of Traumatic Stress, 4 Sep 2026.

Tags: Human, MDMA, PTSD.

Weekly Science Digest, 5 Sep 2026 to 11 Sep 2026, finding 3: This week's human data

MDMA meta-analysis stays positive; a psilocybin smoking cohort cut craving but not abstinence.

Pooling seven RCTs (published and unpublished, none retracted), MDMA-assisted therapy improved PTSD severity, dissociation, depression and functional impairment, but not sleep. In an observational smoking cohort, psilocybin-assisted care beat standard care on reduction and early urge scores while the adjusted abstinence odds ratio was 1.82 (95% CI 0.68-4.86).

Weekly Science Digest, 29 Aug 2026 to 4 Sep 2026, finding 2: The human evidence, honestly

This week's clinical reports were small, uncontrolled, or negative.

An MDMA-assisted couples therapy protocol for veteran PTSD reported preliminary benefit in eight couples, open-label with no control group. A review of the alcohol use disorder literature concludes the evidence is still too sparse and expectancy-biased to put psychedelics near naltrexone or acamprosate.

Read the original

—
Node—
Statuslive
Throughput—